There are currently 2028 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763
Recruiting
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2025
Locations: Rush University Medical Center- Site Number : 8400014, Chicago, Illinois
Conditions: Hemophilia A
Register for Updates
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: John H Stroger Jr Hospital of Cook County, Chicago, Illinois +1 locations
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Register for Updates
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776
Recruiting
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
Register for Updates
The COCOA-PAD II Trial
NCT04794530
Recruiting
Among people with peripheral artery disease (PAD) age 55 and older, the investigators will test the hypothesis that PAD participants randomized to cocoa flavanols will have greater improvement or less decline in six-minute walk distance at six-month follow-up, compared to those randomized to placebo. The study will randomize 190 participants with PAD age 55 and older to one of two groups for six months: cocoa flavanols vs placebo. Our primary outcome is change in six-minute walk distance at six-... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/12/2025
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Peripheral Artery Disease
Register for Updates
Analysis of Human ALS Tissues and Registry of ALS Patients
NCT05067179
Recruiting
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. This devastating disorder afflicts people in the prime of their lives. At the present time, there are no cures for this disorder, and current treatments are marginal at best. Despite years of intensive research, a fundamental understanding of this disease is still lacking. There is a n... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/12/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
NCT05451004
Recruiting
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Oropharyngeal Cancer
Register for Updates
Formative Usability Assessment of Wireless Thermal Anisotropy Devices
NCT06040697
Recruiting
Measurements of shunt flow will be performed non-invasively. This study will generate usability data via observed tasks and comprehension questions to enable future device design improvements.
Gender:
ALL
Ages:
Between 5 years and 80 years
Trial Updated:
05/12/2025
Locations: Rhaeos, Inc., Chicago, Illinois
Conditions: Hydrocephalus
Register for Updates
Longitudinal Measurements of Flow in Cerebrospinal Fluid Shunts With a Wireless Thermal Anisotropy Measurement Device
NCT06086561
Recruiting
This study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (CSF) shunt flow. Patients with an existing implanted shunt will wear the device to acquire longitudinal data.
Gender:
ALL
Ages:
Between 5 years and 80 years
Trial Updated:
05/12/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois +1 locations
Conditions: Hydrocephalus
Register for Updates
WeCanManage. An mHealth Self-management Tool
NCT06185738
Recruiting
Examine the Feasibility, Acceptability, User Satisfaction, and Response Patterns and Preliminary Efficacy on Targeted Patient Reported Outcomes. Using a pre-post, single arm feasibility design with cancer survivors with disabilities
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: University of Illinois, Chicago, Illinois
Conditions: Breast Cancer, Head and Neck Cancer, Sarcoma
Register for Updates
Remote Therapeutic Monitoring Exercise Tracking
NCT06306768
Recruiting
The purpose of this study is to examine physical activity and exercise behaviors in people with Parkinson's Disease and Multiple Sclerosis over the course of 1-year using a cloud-based remote monitoring platform.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
05/12/2025
Locations: Shirley Ryan AbilityLab, Chicago, Illinois
Conditions: Parkinson Disease, Multiple Sclerosis
Register for Updates
Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
NCT06892704
Recruiting
The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are: 1. Does obstruction of the olfactory cleft predict return of the sense of smell? 2. Do electrophysiological signals generated by breathing and sniffing behavior predict return of the sense of smell? Participants starting dupilumab will undergo assessment for their degr... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/12/2025
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Smell Loss
Register for Updates
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648
Recruiting
The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma. The main questions this trial aims to answer are whether combined PVE and HVE increases the proportion of patients who be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Register for Updates